Key statistics
On Friday, Roivant Sciences Ltd (87S:DEU) closed at 11.02, -5.73% below its 52-week high of 11.69, set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.78 |
---|---|
High | 11.02 |
Low | 10.42 |
Bid | 11.04 |
Offer | 11.13 |
Previous close | 10.90 |
Average volume | 1.15k |
---|---|
Shares outstanding | 739.52m |
Free float | 512.15m |
P/E (TTM) | 2.13 |
Market cap | 8.78bn USD |
EPS (TTM) | 5.57 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
- Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
- Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
- Roivant Provides Update on Graves’ Disease Development Program
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
- Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
More ▼